Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity [Yahoo! Finance]
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024